Top

Published in:

01-01-2017 | Neurology and Preclinical Neurological Studies - Original Article

A single dose of l-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson’s disease

Authors: Orsolya Györfi, Helga Nagy, Magdolna Bokor, Oguz Kelemen, Szabolcs Kéri

Published in: Journal of Neural Transmission | Issue 1/2017

Abstract

Despite the well-known neuropsychiatric side effects of dopaminergic medications, the possible subjective psychotomimetic effects of a single dose of l-DOPA in newly diagnosed, drug-naïve patients with Parkinson’s disease (PD) are not known. To investigate this question, we used a visual search task for latent inhibition (LI), the Community Assessment of Psychic Experiences (CAPE) scale, and visual analog scales for psychotomimetic effects (perception, relaxation, and dysphoria) in 28 de novo PD patients before (off) and after (on) the adminstration of l-DOPA and in 25 matched healthy control individuals. Results revealed increased LI in PD-off and decreased LI in PD-on relative to the control subjects. After the administration of l-DOPA, we observed a significant decline in LI in PD. l-DOPA also enhanced perceptual experiences (changes in subjective feelings in thinking, time perception, and mental “highness”). Greater reduction in LI was associated with enhanced perceptual experiences. These results suggest that a single dose of l-DOPA has a significant psychotomimetic effect, which is associated with decreased LI, a behavioral marker of psychosis-like experiences.

Allman MJ, Meck WH (2012) Pathophysiological distortions in time perception and timed performance. Brain 135:656–677CrossRefPubMed

Andreou C, Bozikas VP, Luedtke T, Moritz S (2015) Associations between visual perception accuracy and confidence in a dopaminergic manipulation study. Front Psychol 6:414CrossRefPubMedPubMedCentral

Artieda J, Pastor MA, Lacruz F, Obeso JA (1992) Temporal discrimination is abnormal in Parkinson’s disease. Brain 115:199–210CrossRefPubMed

Austin G, Hayward W (1969) Time perception in patients with depressed consciousness and Parkinson’s disease I. Experimental results. Confin Neurol 31(1):22–36CrossRefPubMed

Birkmayer W, Hornykiewicz O (1961) The l-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787–788PubMed

Bodis-Wollner I (2009) Retinopathy in Parkinson Disease. J Neural Transm (Vienna) 116(11):1493–1501CrossRef

Bodis-Wollner I, Yahr MD, Mylin L, Thornton J (1982) Dopaminergic deficiency and delayed visual evoked potentials in humans. Ann Neurol 11(5):478–483CrossRefPubMed

Braunstein-Bercovitz H, Lubow RE (1998) Are high-schizotypal normal participants distractible or limited in attentional resources? A study of latent inhibition as a function of masking task load and schizotypy level. J Abnorm Psychol 107(4):659–670CrossRefPubMed

Büttner T, Kuhn W, Patzold T, Przuntek H (1994) l-DOPA improves colour vision in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 7(1):13–19CrossRefPubMed

Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311(16):1670–1683CrossRefPubMed

Escobar M, Oberling P, Miller RR (2002) Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia. Neurosci Biobehav Rev 26(2):203–216CrossRefPubMed

Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59(5):852–858CrossRefPubMed

Geffe S, Schindlbeck KA, Mehl A, Jende J, Klostermann F, Marzinzik F (2016) The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson’s disease. J Neural Transm (Vienna) 123(6):601–610CrossRef

Ghilardi MF, Bodis-Wollner I, Onofrj MC, Marx MS, Glover AA (1988) Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 111(1):131–149CrossRefPubMed

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentral

Jiménez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz MC (2015) Dyskinesias and impulse control disorders in Parkinson’s disease: from pathogenesis to potential therapeutic approaches. Neurosci Biobehav Rev 56:294–314CrossRefPubMed

Jones CR, Jahanshahi M (2014) Motor and perceptual timing in Parkinson’s disease. Adv Exp Med Biol 829:265–290CrossRefPubMed

Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160(1):13–23CrossRefPubMed

Kéri S (2011) Solitary minds and social capital: latent inhibition, general intellectual functions and social network size predict creative achievements. Psychol Aesth Creat Arts 5:215–221CrossRef

Kleinloog D, Roozen F, De Winter W, Freijer J, Van Gerven J (2014) Profiling the subjective effects of ∆⁹-tetrahydrocannabinol using visual analogue scales. Int J Methods Psychiatr Res 23(2):245–256CrossRefPubMed

Kleinloog D, Rombouts S, Zoethout R, Klumpers L, Niesters M, Khalili-Mahani N, Dahan A, van Gerven J (2015) Subjective Effects of ethanol, morphine, Δ(9)-tetrahydrocannabinol, and ketamine following a pharmacological challenge are related to functional brain connectivity. Brain Connect 5(10):641–648CrossRefPubMed

Konings M, Bak M, Hanssen M, van Os J, Krabbendam L (2006) Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand 114(1):55–61CrossRefPubMed

Lang AE, Fahn S (1989) Assessment of Parkinson’s disease. In: Munsat TL (ed) Quantification of neurologic deficit. Butterworth-Heinemann, Boston, pp 285–309

Lange KW, Tucha O, Steup A, Gsell W, Naumann M (1995) Subjective time estimation in Parkinson’s disease. J Neural Transm Suppl 46:433–438PubMed

Liggins J, Pihl RO, Benkelfat C, Leyton M (2012) The dopamine augmenter l-DOPA does not affect positive mood in healthy human volunteers. PLoS One 7(1):e28370CrossRefPubMedPubMedCentral

Lubow RE (1973) Latent inhibition. Psychol Bull 79(6):398–407CrossRefPubMed

Lubow RE, Weiner I (2010) Latent inhibition: cognition, neuroscience, and application to schizophrenia. Cambridge University Press, CambridgeCrossRef

Lubow RE, Dressler R, Kaplan O (1999) The effects of target and distractor familiarity on visual search in de novo Parkinson’s disease patients: latent inhibition and novel pop-out. Neuropsychology 13(3):415–423CrossRefPubMed

Lubow RE, Kaplan O, Abramovich P, Rudnick A, Laor N (2000) Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophr Res 45(1–2):145–156CrossRefPubMed

Nagy H, Levy-Gigi E, Somlai Z, Takáts A, Bereczki D, Kéri S (2012) The effect of dopamine agonists on adaptive and aberrant salience in Parkinson’s disease. Neuropsychopharmacology 37(4):950–958CrossRefPubMed

Polner B, Moustafa AA, Nagy H, Takáts A, Györfi O, Kéri S (2016) Dopamine improves exploration after expectancy violations and induces psychotic-like experiences in patients with Parkinson’s disease. Neurosci Lett 616:132–137CrossRefPubMed

Rutledge RB, Skandali N, Dayan P, Dolan RJ (2015) Dopaminergic modulation of decision making and subjective well-being. J Neurosci 35(27):9811–9822CrossRefPubMedPubMedCentral

Schmidt-Hansen M, Le Pelley M (2012) The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)? Cogn Neuropsychiatry 17(6):473–505CrossRefPubMed

Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Sharp R, Auerbach PP (2003) Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology 169(3–4):314–320CrossRefPubMed

Weiner I, Arad M (2009) Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res 204(2):369–386CrossRefPubMed

Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91(2):248–253CrossRefPubMed

Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30(4):871–878CrossRefPubMed

Weintraub D, Burn DJ (2011) Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 26(6):1022–1031CrossRefPubMedPubMedCentral

Title: A single dose of l-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson’s disease
Authors: Orsolya Györfi
Helga Nagy
Magdolna Bokor
Oguz Kelemen
Szabolcs Kéri
Publication date: 01-01-2017
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 1/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-016-1630-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A single dose of l-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Neuromolecular imaging, a nanobiotechnology for Parkinson’s disease: advancing pharmacotherapy for personalized medicine

Phytochemicals prevent mitochondrial membrane permeabilization and protect SH-SY5Y cells against apoptosis induced by PK11195, a ligand for outer membrane translocator protein

Nanomedicine in brain repair: Alzheimer’s, Parkinson’s and the proteome

Proteomic profile of embryonic stem cells with low survival motor neuron protein is consistent with developmental dysfunction

Vagus nerve stimulation in psychiatry: a systematic review of the available evidence

Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats